{
  "abstract": "The efficacy of dendritic cell (DC) vaccines in cancer immunotherapy is often limited by weak immunogenicity due to inefficient antigen cross‐presentation (XPT). We previously combined a calcium carbonate (CaCO3) delivery system with a proteolysis‐targeting chimera (PROTAC) to enhance antigen degradation. Along this line, we developed a protein/DNA‐integrated nanoantigen platform (HpOAC) co‐loading CaCO3 with a His‐tagged ovalbumin (O) modified with the von Hippel‐Lindau (VHL) E3 ligase‐recruiting peptide ALAPYIP (HOA) and a eukaryotic plasmid encoding O‐ALAPYIP (pOA). HpOAC promoted DC maturation and migration via Ca2+ release. Mechanistically, HOA provided an immediate antigen source, while pOA enabled sustained expression; both underwent ALAPYIP‐mediated VHL recruitment, enhancing O ubiquitination and proteasomal degradation, thereby amplifying XPT. Consequently, HpOAC‐DCs induced strong OT‐I/OT‐II T cell proliferation in vitro. In vivo, a single immunization with HpOAC‐DCs significantly suppressed tumor growth and elicited durable antigen‐specific T helper type 1 and cytotoxic T lymphocyte responses, outperforming single‐antigen vaccines. Under a two‐dose regimen, its anti‐tumor efficacy was improved compared to non‐PROTAC and in situ antigen vaccines. Thus, we constructed a PROTAC‐enhanced, protein/DNA‐integrated DC vaccine platform that synergizes immediate and sustained antigen supply with Ca2+‐mediated adjuvanticity, offering a highly promising strategy for novel DC vaccine design.",
  "abstract_shown": true,
  "affiliations": [
    "Xinjiang Key Laboratory of Biological Resources and Genetic Engineering College of Life Science and Technology Xinjiang University Urumqi China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Peng Liu",
      "orcid": "0009-0001-9100-4706"
    },
    {
      "affs": [
        0
      ],
      "name": "Qiang Chen",
      "orcid": "0009-0005-3500-6634"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhe Zhou"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuekang Xu",
      "orcid": "0000-0002-1100-3982"
    },
    {
      "affs": [
        0
      ],
      "name": "Jinyao Li",
      "orcid": "0000-0002-3295-6096"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4c0kb92dc1zjq.bib",
  "cited_by": 0,
  "doi": "10.1002/advs.77089",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13460275/",
  "id": "4c0kb92dc1zjq",
  "issns": [
    "2198-3844"
  ],
  "landing_url": "https://doi.org/10.1002/advs.77089",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2403|Immunotherapy and Immune Responses"
    ]
  ],
  "openalex": "W7202195086",
  "pdf_url": null,
  "pmcid": "PMC13460275",
  "pmid": "42579297",
  "published": "2026-08-11",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/4c0kb92dc1zjq.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:11Z",
      "native_id": "PMC13460275",
      "source": "pmc",
      "url": "https://doi.org/10.1002/advs.77089"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Immunotherapy and Immune Responses",
      "subfield": "immunology"
    }
  ],
  "title": "PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy",
  "title_text": "PROTAC‐Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:20:29Z",
  "url": "https://research.draconitic.com/paper/4c0kb92dc1zjq",
  "venue": "Advanced Science",
  "versions": []
}